Indoco launches FEVINDO 400

Hyderabad, Oct.4 :Indoco Remedies announced the launch of FEVINDO(Favipiravir) 400 mg Tablets in India. Fevindo – 400 (Favipiravir) is an antiviral drug, effectiveagainst the RNA-based influenza virus. The drug has been approved by DCGI in thetreatment of Covid-19. Fevindo 400 reduces pill burden by 50% and ensures convenientdosing and better patient compliance.

In a statement here today, AditiKarePanandikar, Managing Director – Indoco Remedies Ltd. commented, “TheCovid-19 crisis has created vast disruption to life in India and all over the globe. As part ofpharma industry, we have been able to do our bit in prevention of Covid-19 with our brands

Karvol Plus, ATM, Febrex Plus and Rexidin SRS Mouthwash. With the launch of FEVINDO, we

are taking the next step from prevention to the treatment of Covid-19.” Fevindo – 400 (Favipiravir) will be made available at all government approved COVID carecentres and selected medical practitioners across the country. In addition to Fevindo, Indocohas two more new products for launch in Covid Care range, i.e., Povidone Iodine Gargle andImmunity booster chewable tablets with Zinc, Vitamin C and Vitamin D.

Indoco has always been committed to provide quality medicines at affordable prices andwith the launch of these products, the Company is all set to venture into the treatment ofCovid-19.  (NSS)